CN115942929A - Oil-in-water type emulsion composition - Google Patents

Oil-in-water type emulsion composition Download PDF

Info

Publication number
CN115942929A
CN115942929A CN202180041818.6A CN202180041818A CN115942929A CN 115942929 A CN115942929 A CN 115942929A CN 202180041818 A CN202180041818 A CN 202180041818A CN 115942929 A CN115942929 A CN 115942929A
Authority
CN
China
Prior art keywords
oil
composition
mass
logp
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041818.6A
Other languages
Chinese (zh)
Inventor
宫原令二
藤卷大树
重川宏美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of CN115942929A publication Critical patent/CN115942929A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

Provided is an oil-in-water emulsion composition which is excellent in emulsion stability and contains a drug that is easily caused to agglomerate oil droplets and has the property of being dissolved in both an oil phase and an aqueous phase. The oil-in-water type emulsion composition of the present disclosure comprises an aqueous dispersion medium, and oil droplets dispersed in the aqueous dispersion medium, the oil droplets comprising a medicinal agent, a surfactant, and an oil component, and the medicinal agent having a LogP value of-0.7 to 4.0, the surfactant comprising specific three nonionic surfactants, and an anionic surfactant.

Description

Oil-in-water type emulsion composition
Technical Field
The present disclosure relates to oil-in-water emulsion compositions.
Background
For example, in the fields of cosmetics, quasi drugs, and pharmaceuticals, oil-in-water emulsion compositions containing drugs and the like have been developed.
Patent document 1 discloses an oil-in-water emulsified cosmetic composition containing 0.1 to 5% by mass of hydrogenated polyisobutene having a number average molecular weight of 2,000 to 3,000, less than 0.1 to 1% by mass of a higher alcohol, 1 to 25% by mass of an oil component containing an oil-soluble drug and the like, 0.3 to 5% by mass of a surfactant, 0.05 to 5% by mass of a water-soluble thickener, and an aqueous component, wherein the amount of a nonpolar oil component mixed is 30% or less based on the total amount of the oil component.
Patent document 2 discloses an oil-in-water type cosmetic composition containing at least 1 oil, at least 1 polyglyceryl fatty acid ester having 4 to 6 polyglyceryl moieties derived from glycerin, a hydrotrope such as at least 1 whitening agent having a logP of-0.7 to 6, and water.
Patent document 3 discloses an oil-in-water type external composition for skin containing a specific polyoxyethylene dialkyl ester and/or polyoxyethylene dialkyl ether, a specific polyoxyethylene alkyl ester and/or polyoxyethylene alkyl ether, a specific polyoxyethylene sterol ether, and a drug such as phospholipid or lecithin.
Documents of the prior art
Patent document
Patent document 1: international publication No. 2013/046770
Patent document 2: japanese unexamined patent publication No. 2014-122195
Patent document 3: international publication No. 2017/131217
Non-patent document
Non-patent document 1: sakamoto, K., lochhead, R., maibach, H.I., yamashita, Y.A., eds., "Cosmetic Science and Technology: the Cosmetic Principles and Applications", amsterdam, the Netherlands, elsevier,2017, pp.489-506
Disclosure of Invention
Problems to be solved by the invention
In the fields of cosmetics, quasi drugs, drugs and the like, drugs such as phenylethyl resorcinol, salicylic acid and the like are used. These agents are of relatively low molecular weight and have the property of being soluble in both the oil and water phases. When such a drug is mixed in the oil phase (oil droplets) of the oil-in-water emulsion composition, the drug is repeatedly moved to the oil phase and the water phase by a temperature change without being continuously held in the oil phase. As a result, a phenomenon called ostwald ripening, which induces coalescence of oil droplets, as disclosed in non-patent document 1, is likely to occur, and it is therefore difficult to obtain a stable emulsion composition.
Accordingly, the subject matter of the present disclosure is to provide an oil-in-water type emulsion composition excellent in emulsion stability, which contains a drug agent that easily induces coalescence of oil droplets and has a property of being dissolved in both an oil phase and an aqueous phase.
Means for solving the problems
(plan 1)
An oil-in-water emulsion composition comprising:
an aqueous dispersion medium, and
oil droplets dispersed in the aqueous dispersion medium,
the oil droplets contain a medicament, a surfactant and an oil component,
the above-mentioned agents have a LogP value of-0.7 to 4.0,
the surfactant includes a nonionic surfactant represented by the following formula 1 to 3 and an anionic surfactant,
Figure BDA0003990713500000021
in the formula 1, the first and second groups,
R 1 is a linear acyl group or a linear alkyl group having 16 to 24 carbon atoms,
R 2 is an alkyl group having 2 to 4 carbon atoms,
R 3 is a linear acyl group or a linear alkyl group having 16 to 24 carbon atoms,
k is an integer of 4 to 15;
Figure BDA0003990713500000031
in the formula 2, the first and second groups,
R 4 is a straight-chain fatty acid residue or a straight-chain fatty alcohol residue with 16 to 24 carbon atoms,
R 5 is an alkyl group having 2 to 4 carbon atoms,
k is an integer of 5 to 20;
Figure BDA0003990713500000032
in the formula 3, the first and second groups,
R 6 is a cholesterol residue or a phytosterol residue,
R 7 is an alkyl group having 2 to 4 carbon atoms,
k is an integer of 5 to 30.
(plan 2)
The composition according to claim 1, wherein the content of the drug in the composition is 0.1 to 5% by mass based on the total amount of the composition.
Scheme 3
The composition according to claim 1 or 2, wherein the nonionic surfactant represented by the above formula 1 is contained in the composition in an amount of 0.1 to 2% by mass based on the total amount of the composition,
the content of the nonionic surfactant of the formula 2 in the composition is 0.1 to 2% by mass based on the total amount of the composition,
the content of the nonionic surfactant of the formula 3 in the composition is 0.3 to 6% by mass based on the total amount of the composition,
the content of the anionic surfactant in the composition is 0.01 to 0.1% by mass based on the total amount of the composition.
(case 4)
The composition according to any one of aspects 1 to 3, wherein the anionic surfactant is at least one selected from the group consisting of alkanoyl-N-alkyltaurates and alkanoyl glutamates.
Scheme 5
The composition according to any one of aspects 1 to 4, wherein the above-mentioned agent is at least one selected from the group consisting of phenylethyl resorcinol, 4- (1-phenylethyl) -1, 3-diol, phenoxythiazolidine carboxylic acid, nicotinamide, xanthine, ellagic acid, ferulic acid, apigenin, salicylic acid, phloretin, resveratrol and perfume.
Scheme 6
The composition according to any one of claims 1 to 5, wherein the oil component is at least one selected from the group consisting of liquid oils and fats, solid oils and fats, waxes, hydrocarbon oils, higher fatty acids, synthetic ester oils and silicone oils.
Scheme 7
The method for producing an oil-in-water emulsion composition according to any one of claims 1 to 6, wherein a 1 st aqueous phase part comprising the nonionic surfactant and the anionic surfactant of the formulae 1 to 3 and water is prepared,
preparing an oil phase part containing the drug and the oil component,
mixing the oil phase part with part or all of the 1 st aqueous phase part to prepare a pre-emulsion,
mixing the pre-emulsion with the remainder of the 1 st aqueous phase portion, or mixing the pre-emulsion with a 2 nd aqueous phase portion comprising water.
(plan 8)
The process according to claim 7, wherein the aqueous phase 1 contains at least one diol component selected from the group consisting of dipropylene glycol, 1, 3-butanediol, propylene glycol, and polyethylene glycol.
Scheme 9
The production process according to claim 8, wherein the content of the diol component is 40 to 80% by mass based on the total amount of the first aqueous phase portion 1.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the present disclosure, an oil-in-water emulsion composition having excellent emulsion stability, which contains a drug that is easily induced to coalescence of oil droplets and has a property of being dissolved in both an oil phase and an aqueous phase, can be provided.
Detailed Description
Hereinafter, embodiments of the present disclosure will be described in detail. The present disclosure is not limited to the following embodiments, and various modifications can be made within the scope of the invention.
The oil-in-water emulsion composition (sometimes simply referred to as "composition") of the present disclosure includes an aqueous dispersion medium, and oil droplets dispersed in the aqueous dispersion medium, the oil droplets including a drug, a surfactant, and an oil component, the drug having a LogP value of-0.7 to 4.0, the surfactant including the nonionic surfactant and the anionic surfactant of formulae 1 to 3 described above. Here, the "LogP value" is a parameter indicating the ease of distribution of a substance to water and octanol, and is a numerical value generally used as an index for determining the degree of hydrophilicity or hydrophobicity of a substance. The smaller the LogP value, the more hydrophilic the product, and the larger the LogP value, the more hydrophobic the product.
Although not limited by the principle, it is considered that the oil-in-water emulsion composition of the present disclosure has an excellent action principle of emulsion stability even when it contains a drug which is easily induced to coalescence of oil droplets and has a property of being dissolved in both an oil phase and an aqueous phase (this property is sometimes referred to as "water-solubilizing growth property"), that is, a drug which is easily induced to coalescence of oil droplets.
In the case of an oil-in-water emulsion composition, the surfactant is generally oriented in a film-like manner at the interface between the oil phase and the water phase, that is, around the oil droplets. Surfactants oriented at such interfaces typically do not remain continuously held at the interface, moving between the interface and the aqueous phase. As a result, the surfactant can be temporarily moved around the oil droplets to form a position where the surfactant does not exist.
It is considered that the medicament having hydrotropic property can pass through a site where the surfactant does not exist, and therefore induces coalescence of oil droplets in the oil-in-water emulsion composition.
For example, patent document 3 discloses a technique for improving emulsion stability by forming a stronger interface film at the interface of oil droplets using a specific surfactant. Patent document 3 describes that a drug such as phospholipid, lecithin, lysolecithin, or ceramide can be used, but these drugs do not have the water-solubilizing growth-promoting property that is sought in the present disclosure. As long as the agent is a phospholipid, lecithin, or the like, good emulsion stability can be ensured by the technique described in patent document 3. However, when the drug having water-assisted growth properties, which is intended in the present disclosure, is used, the technique described in patent document 3 cannot prevent such a drug from passing through the interface film, and thus cannot obtain good emulsion stability.
The composition of the present disclosure includes an anionic surfactant as a surfactant in addition to the nonionic surfactants of formulae 1 to 3. Since the nonionic surfactants of formulae 1 to 3 have relatively similar properties, an interface film associated with these nonionic surfactants can be formed around oil droplets without causing problems such as crystal precipitation and viscosity increase. In addition, it is considered that an electrolyte layer is also formed together with the anionic surfactant. As a result, it is considered that the interface film formed of a nonionic surfactant can be reinforced with an electrolyte layer accompanied by an anionic surfactant, and the passage of a chemical having a water-assisted growth property through the interface film can be reduced or suppressed, and thus good emulsion stability can be obtained.
Oil-in-water type emulsion composition
The oil-in-water emulsion composition of the present disclosure has excellent emulsion stability. Here, the emulsion stability may mean, for example, a state that is not separated in an emulsion stability test of 30 days at 50 ℃ and/or 30 days under a temperature cycle of 0 to 40 ℃ described later, and is preferably a state in which a change in the size of the emulsion particles (oil droplets) is small. In addition, since such an emulsion stability test corresponds to a promotion test, an emulsion composition having good results in such a test can obtain more excellent emulsion stability performance at normal temperature (for example, 5 to 35 ℃).
In some embodiments, the increase rate of oil droplets in at least 1 of the above emulsion stability tests may be suppressed to 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less. The lower limit of the increase rate of oil droplets is not particularly limited, and may be, for example, 0% or more than 0%. The increase rate can be calculated from the initial value of the average particle size of the oil droplets (value immediately after production) and the value of the average particle size of the oil droplets after the emulsion stability test, by the following formula 4:
increase rate (%) = { (value of average particle size of oil droplets after emulsion stability test-initial value of average particle size of oil droplets) × 100 }/(initial value of average particle size of oil droplets) \82304: (formula 4)
Aqueous dispersion medium
The oil-in-water type emulsion composition of the present disclosure contains an aqueous dispersion medium. The aqueous dispersion medium is typically composed of water, but various water-soluble or water-dispersible components among the optional components described below may be optionally blended in the aqueous dispersion medium.
The water that can be used in the oil-in-water emulsion composition of the present disclosure is not particularly limited, and water that can be used in cosmetics, quasi drugs, and the like can be used. For example, ion-exchanged water, distilled water, ultrapure water, tap water, or the like can be used.
The amount of water to be blended is not particularly limited, and may be, for example, 30 mass% or more, 40 mass% or more, or 50 mass% or more, or 90 mass% or less, 80 mass% or less, 70 mass% or less, 60 mass% or less, or 50 mass% or less, relative to the total amount of the composition, from the viewpoint of emulsion stability, usability, and the like.
Oil drop
Oil droplets, which are an oil phase or a dispersed phase in an oil-in-water type emulsion composition, contain a medicament, a surfactant, and an oil component.
The average particle size of the oil droplets is not particularly limited, and may be, for example, 0.3 μm or more, 0.5 μm or more, 0.7 μm or more, or 1 μm or more immediately after the production, or 50 μm or less, 40 μm or less, 30 μm or less, 20 μm or less, or 10 μm or less. Here, the average particle size of the oil droplets may be defined as an average value of projected area equivalent circle diameters of 10 or more, preferably 100 or more oil droplets observed with an optical microscope.
(agent)
The oil-in-water emulsion composition of the present disclosure contains, as a medicament, at least a medicament having a LogP value of-0.7 to 4.0. A drug having such a LogP value can be said to have water-solubilizing properties that tend to lower the emulsion stability of a general oil-in-water emulsion composition. The range of the LogP value may be-0.7 or more, -0.5 or more, -0.3 or more, -0.1 or more, 0 or more, or 0.5 or more, and may be 4.0 or less, 3.7 or less, or 3.5 or less. The LogP value can be calculated using, for example, calculation software (PALAAS, manufactured by CompDrug Chemistry Ltd.).
The content of such a drug is not particularly limited, and may be, for example, 0.1 mass% or more, 0.3 mass% or more, 0.5 mass% or more, 0.7 mass% or more, or 1 mass% or more, and further may be 5 mass% or less, 4 mass% or less, 3 mass% or less, 2 mass% or less, or 1 mass% or less, with respect to the total amount of the composition, from the viewpoints of drug efficacy, emulsion stability, and the like.
Specific examples of the pharmaceutical agent having a LogP value of-0.7 to 4.0 include phenylethylresorcinol (LogP: 3.4), 4- (1-phenylethyl) -1, 3-diol (LogP: 3.5), phenoxythiazolidinecarboxylic acid (LogP: -0.1), nicotinamide (LogP: -0.4), xanthine (LogP: -0.7), ellagic acid (LogP: 1.1), ferulic acid (LogP: 1.5), apigenin (LogP: 1.7), salicylic acid (LogP: 2.3), phloretin (LogP: 2.6), resveratrol (LogP: 3.1), and the like. The agents may be used alone or in combination of two or more.
The oil-in-water emulsion composition of the present disclosure may also contain a perfume as such an agent. According to the oil-in-water emulsion composition of the present disclosure, a fragrance can be stably compounded without compounding an alcohol such as ethanol. The perfumes may be used singly or in combination of two or more.
As perfumes having a LogP value of-0.7 to 4.0, there may be mentioned, for example, anisaldehyde (LogP: 1.8), benzyl acetate (LogP: 2.0), benzyl alcohol (LogP: 1.1), carane (LogP: 1.8), sympathonal (LogP: 2.0), cis-3-hexenol (LogP: 1.4), coumarin (LogP: 1.4), ethyl acetate (LogP: 0.7), ethyl acetoacetate (LogP: 0.3), ethyl butyrate (LogP: 1.8), ethyl maltol (LogP: 0.5), ethyl vanillin (LogP: 1.8), apple ester (LogP: 0.8), heliotropin (LogP: 1.4), heliotropin (LogP: 1.1), heliotropin (LogP: 1241.5), indole (LogP.1251251251251251.1251), geranyl alcohol (LogP.1251251.1251), geranyl alcohol (LogP.1251251.1241.1251), geranyl alcohol (LogP, 1251251251.1251251.5), linalool (LogP) (LogP.1251251251251251.1241.1251.1251.1251.1251.1251.1251.1251, 1251.1251.1251, 1255) α -dihydrodamascone (LogP: 3.6), aldehyde C-14 (LogP: 3.8), aldehyde C-16 (LogP: 2.8), allylamyl glycolate (LogP: 2.5), benzyl benzoate (LogP: 3.9), 3- (4-tert-butylphenyl) propionaldehyde (LogP: 3.5), cis-3-hexenylacetate (LogP: 2.3), citral (LogP: 3.1), citronellol (LogP: 3.3), delta-dihydrodamascone (LogP: 3.6), dihydromyrcenol (LogP: 3.0), oridonone (LogP 12412412412412412412412412412412452124125 (LogP: 2.1), eucalyptol (LogP: 2.8), eugenol (LogP: 2.1251251251251251251251251254), pterocarcinol (LogP), rhabdominal (LogP.1251251255) (LogP 2.1251251251255, lagP (LogP) and 4 (LogP.1251251255) <xnotran> l- (LogP: 3.2), l- (LogP: 2.8), (LogP: 2.2), (LogP: 2.6), (LogP: 2.4), (PAMPLEFLEUR, パンプルフルール (LogP: 3.0), (LogP: 2.9), ポアレネート (LogP: 3.7), リュバフラン (LogP: 2.8), (LogP: 2.9), (LogP: 2.3), (LogP: 2.8), (LogP: 2.6), (LogP: 3.6), (LogP: 3.5), テトラヒドロムゴール (LogP: 3.5), (LogP: 2.4), (LogP: 2.9), 2,4- -3- -1- (LogP: 2.4), (LogP: 3.7) (LogP: 3.5), (Geraniol) (LogP: 3.6), (LogP: 2.1), (LogP: 2.9). </xnotran>
(surfactant)
The oil-in-water emulsion composition of the present disclosure contains at least a nonionic surfactant represented by the following formula 1 to formula 3 and an anionic surfactant as a surfactant.
a. A nonionic surfactant of formula 1
As the surfactant, a nonionic surfactant of the following formula 1 was used. The surfactant is a double-chain type nonionic surfactant having 2 hydrophobic groups. Such surfactants may be used alone or in combination of two or more kinds:
Figure BDA0003990713500000091
in formula 1, R 1 Is a linear acyl group or a linear alkyl group having 16 to 24 carbon atoms, R 2 Is an alkyl group having 2 to 4 carbon atoms, R 3 Is a C16-24 linear acyl group or a linear alkyl group, and k is an integer of 4 to 15.
As R 1 And R 3 The number of carbon atoms of (a) may be 16 or more, 17 or more, or 18 or more, and may be 24 or less, 23 or less, or 22 or less, independently of each other. R is 2 The number of carbon atoms of (2) is preferably 2 to 3, more preferably 2. Further, k may be 4 or more, 5 or more, 6 or more, or 7 or more, or 15 or less, 14 or less, or 13 or less.
Specific examples of the nonionic surfactant of formula 1 include polyoxyethylene (4 mol) distearic acid, polyoxyethylene (6 mol) distearic acid, polyoxyethylene (8 mol) distearic acid, polyoxyethylene (12 mol) distearic acid, steareth-4-stearate, steareth-6-stearate, steareth-9-stearate, polyoxyethylene (8 mol) dibehenyl ether, and the like. Here, the bonding form of the polyoxyethylene chain and the alkyl group may be an ester bond or an ether bond, or both of them may be contained.
The content of the nonionic surfactant of formula 1 is not particularly limited, and may be, for example, 0.1 mass% or more or 0.2 mass% or more, or 2 mass% or less, 1 mass% or less, 0.7 mass% or less, or 0.5 mass% or less with respect to the total amount of the composition, from the viewpoint of emulsion stability and the like.
b. A nonionic surfactant of formula 2
As the surfactant, a nonionic surfactant of the following formula 2 was used. Such surfactants may be used alone or in combination of two or more:
Figure BDA0003990713500000101
in formula 2, R 4 Is a straight chain fatty acid residue or a straight chain fatty alcohol residue with 16 to 24 carbon atoms, R 5 Is an alkyl group having 2 to 4 carbon atoms, and k is an integer of 5 to 20.
As R 4 The number of carbon atoms of (b) may be 16 or more, 17 or more, or 18 or more, and further, may be 24 or less, 23 or less, or 22 or less. R 5 The number of carbon atoms (2) is preferably 2 to 3, more preferably 2. Further, k may be 5 or more, 6 or more, or 7 or more, or 20 or less, 18 or less, 16 or less, 14 or less, or 12 or less.
From the viewpoint of emulsion stability, ease of formation of an interface film of oil droplets, and the like, the HLB of the nonionic surfactant of formula 2 is preferably 7.0 or more, 8.0 or more, or 9.0 or more, and is preferably 15.0 or less, 14.0 or less, or 13.0 or less. Here, HLB is generally a value indicating the affinity of a surfactant for water and oil, and is a parameter known as a hydrophilic-lipophilic balance, and can be easily obtained by a known calculation method such as griffy.
Specific examples of the nonionic surfactant of formula 2 include polyoxyethylene (20 mol) behenyl ether, polyoxyethylene (10 mol) stearyl ether, and polyoxyethylene (7 mol) cetyl ether.
The content of the nonionic surfactant of formula 2 is not particularly limited, and may be, for example, 0.1 mass% or more or 0.2 mass% or more, or 2 mass% or less, 1 mass% or less, 0.7 mass% or less, or 0.5 mass% or less with respect to the total amount of the composition, from the viewpoint of emulsion stability and the like.
c. A nonionic surfactant of formula 3
As the surfactant, a nonionic surfactant of the following formula 3 (sometimes referred to as "polyoxyalkylene glycol ether") is used. Such surfactants may be used alone or in combination of two or more:
Figure BDA0003990713500000111
in formula 3, R 6 Is a cholesterol residue or a phytosterol residue, R 7 Is an alkyl group having 2 to 4 carbon atoms, and k is an integer of 5 to 30.
R 7 The number of carbon atoms (2) is preferably 2 to 3, more preferably 2. Further, k may be 5 or more, 6 or more, or 7 or more, or 30 or less, 25 or less, 20 or less, 18 or less, 16 or less, 14 or less, or 12 or less.
Specific examples of the nonionic surfactant of formula 3 include polyoxyethylene (10 mol) phytosterol, polyoxyethylene (30 mol) polyoxypropylene (7 mol) phytosterol, polyoxyethylene (10 mol) cholesterol, and polyoxyethylene (20 mol) cholesterol.
The content of the nonionic surfactant of formula 3 is not particularly limited, and may be, for example, 0.3 mass% or more, 0.4 mass% or more, 0.5 mass% or more, 0.6 mass% or more, or 0.7 mass% or more, or 6 mass% or less, 4 mass% or less, 2 mass% or less, or 1 mass% or less with respect to the total amount of the composition, from the viewpoint of emulsion stability or the like.
d. Anionic surfactant
The anionic surfactant is not particularly limited, and examples thereof include polyoxyethylene alkyl ether sulfate, higher fatty acid salts, alkyl ether sulfate, alkanoyl-N-alkyltaurates, and alkanoyl glutamate. The anionic surfactants may be used alone or in combination of two or more. Examples of the salts thereof include alkali metal salts such as sodium, potassium and lithium, and amine salts such as triethanolamine, diethanolamine and monoethanolamine.
Among the above anionic surfactants, at least one selected from the group consisting of alkanoyl-N-alkyltaurates and alkanoyl glutamates is preferable from the viewpoints of the enhancement of the interfacial film by a nonionic surfactant, the emulsion stability accompanying this, and the like. The number of carbon atoms of the alkanoyl group is preferably 12 or more, 13 or more, or 14 or more, and further preferably 22 or less, 21 or less, or 20 or less. Among them, stearoyl is particularly preferable. The alkyl group includes a methyl group, an ethyl group, and a propyl group, and preferably includes a methyl group.
The content of the anionic surfactant is not particularly limited, and may be, for example, 0.01 mass% or more or 0.02 mass% or more, or 0.1 mass% or less, 0.08 mass% or less, 0.06 mass% or less, or 0.05 mass% or less with respect to the total amount of the composition, from the viewpoints of the reinforcement of the interface film formed by the nonionic surfactant, the emulsion stability accompanying this, and the like.
e. Compounding ratio of surfactant
The mixing ratio of the surfactant is not particularly limited, and for example, from the viewpoint of emulsion stability and the like, the mixing ratio of the nonionic surfactant of formula 1, the nonionic surfactant of formula 2, and the nonionic surfactant of formula 3 is preferably in the range of 1.
For example, from the viewpoint of the reinforcing property of the interface film formed by the nonionic surfactant, the emulsion stability accompanying this, and the like, the anionic surfactant is preferably 0.5 parts by mass or more or 1.0 parts by mass or more, and further preferably 10 parts by mass or less, 8.0 parts by mass or less, 5.0 parts by mass or less, or 3.0 parts by mass or less, with respect to 100 parts by mass of the nonionic surfactant of formulae 1 to 3.
(oil component)
The content of the oil component in the oil-in-water emulsion composition of the present disclosure is not particularly limited, and may be, for example, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 3% by mass or more, 5% by mass or more, 7% by mass or more, 10% by mass or more, 13% by mass or more, or 15% by mass or more, or 50% by mass or less, 40% by mass or less, 30% by mass or less, 25% by mass or less, or 20% by mass or less, with respect to the total amount of the composition, from the viewpoint of usability and the like.
The oil component is not particularly limited, and examples thereof include liquid oils and fats, solid oils and fats, waxes, hydrocarbon oils, higher fatty acids, synthetic ester oils, and silicone oils. The oil component may be used alone or in combination of two or more.
Examples of the liquid oil and fat include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn bran oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic oil, wheat germ oil, camellia oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, torreya oil, rice bran oil, baitong oil, jatropha oil, jojoba oil, germ oil, and triglycerin.
Examples of the solid fat include cacao butter, coconut oil, horse fat, hardened coconut oil, palm oil, beef tallow, mutton tallow, hardened beef tallow, palm kernel oil, lard, beef bone fat, beeswax kernel oil, hardened oil, neatsfoot oil, beeswax, and hardened castor oil.
Examples of the waxes include beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, chinese insect wax, spermaceti wax, montan wax, rice bran wax, lanolin, kapok wax, acetylated lanolin, liquid lanolin, sugar cane wax, isopropyl lanolate, hexyl laurate, reduced lanolin, jojoba wax, hard lanolin, shellac wax, polyoxyethylene lanolin alcohol ether, polyoxyethylene lanolin alcohol acetate, polyoxyethylene cholesterol ether, lanolin fatty acid polyglycol ester, polyoxyethylene hydrogenated lanolin alcohol ether, and cetyl palmitate.
Examples of the hydrocarbon oil include liquid paraffin, ceresin, squalane, pristane, paraffin, ceresin, squalene, vaseline, and microcrystalline wax.
Examples of the higher fatty acid include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, undecylenic acid, tall oil acid, isostearic acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).
Examples of the synthetic ester oil include cetyl octanoate, myristyl myristate, glycerol tri-2-ethylhexanoate, pentaerythritol tetra-2-ethylhexanoate, dioctyl succinate, and tripropylene glycol dineovalerate.
Examples of the silicone oil include chain polysiloxanes (e.g., dimethylpolysiloxane, methylphenylpolysiloxane, diphenylpolysiloxane); cyclic polysiloxanes (e.g., octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane), silicone resins forming a 3-dimensional network structure, silicone rubbers, various modified polysiloxanes (e.g., amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, fluorine-modified polysiloxane), acrylic silicones.
(optional ingredients)
The emulsion composition of the present disclosure may optionally contain other components than the above components within a range not affecting the effect of the present invention. Any of the components may be used alone or in combination of two or more, and may be appropriately compounded in an oil phase or an aqueous phase.
Examples of such optional components include powder components, amphoteric surfactants, nonionic surfactants other than those mentioned above (e.g., lipophilic nonionic surfactants and hydrophilic nonionic surfactants), higher aliphatic alcohols, polyhydric alcohols, water-soluble polymers (e.g., natural water-soluble polymers, semisynthetic water-soluble polymers and synthetic water-soluble polymers), ultraviolet absorbers, sequestering agents, pH adjusters, vitamins, antioxidants and antioxidant adjuvants.
Examples of the powder component include inorganic powders (for example, talc, kaolin, mica, sericite (serite), muscovite, phlogopite, synthetic mica, lepidolite, biotite, vermiculite, bentonite, hectorite, \1252112509124901245212412488, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (calcined gypsum), calcium phosphate, fluorapatite, hydroxyapatite, ceramic powder, metal soap (for example, zinc myristate, calcium palmitate, aluminum stearate), and boron nitride); organic powders (e.g., polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, copolymer resin powder of styrene and acrylic acid, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose powder); inorganic white pigments (e.g., titanium dioxide, zinc oxide); inorganic red pigments (e.g., iron oxide (red iron oxide) and iron titanate); inorganic brown pigments (e.g., gamma-iron oxide); inorganic yellow pigments (e.g., yellow iron oxide and yellow soil); inorganic black pigments (e.g., black iron oxide and titanium suboxide); inorganic violet pigments (e.g., manganese violet and cobalt violet); inorganic green pigments (e.g., chromium oxide, chromium hydroxide, cobalt titanate); inorganic blue pigments (e.g., ultramarine blue and navy blue); pearlescent pigments (e.g., titanium oxide-coated mica, titanium oxide-coated bismuth oxychloride, titanium oxide-coated talc, colored titanium oxide-coated mica, bismuth oxychloride, fish scale foil); metal powder pigments (e.g., aluminum powder, copper powder); organic pigments such as zirconium, barium or aluminum lakes (for example, organic pigments such as red 201, red 202, red 204, red 205, red 220, red 226, red 228, red 405, orange 203, orange 204, yellow 205, yellow 401, and blue 404, red 3, red 104, red 106, red 227, red 230, red 401, red 505, orange 205, yellow 4, yellow 5, yellow 202, yellow 203, green 3, and blue 1); natural pigments (e.g., chlorophyll, beta-carotene).
As the amphoteric surfactant, for example, imidazoline amphoteric surfactants are mentionedSurfactants (e.g., 2-undecyl-N, N, N- (hydroxyethylcarboxymethyl) -2-imidazoline sodium, 2-cocoyl-2-imidazoline
Figure BDA0003990713500000151
Hydroxide-1-carboxyethoxy 2 sodium salt); betaine-based surfactant (e.g., 2-heptadecyl-N-carboxymethyl-N-hydroxyethyl imidazoline->
Figure BDA0003990713500000152
Betaine, lauryl dimethyl glycine betaine, alkyl betaine, amide betaine, sulfobetaine).
Examples of the lipophilic nonionic surfactant include sorbitan fatty acid esters (for example, sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerin sorbitan penta-2-ethylhexanoate, diglycerin sorbitan tetra-2-ethylhexanoate); glycerol polyglyceryl fatty acids (e.g., cottonseed oil fatty acid glyceride, erucic acid glyceride, glyceryl sesquioleate, glyceryl monostearate, glycerol pyroglutamate α, α' -oleate, glycerol malate monostearate); propylene glycol fatty acid esters (e.g., propylene glycol monostearate); hardened castor oil derivatives; glycerol alkyl ether.
Examples of the hydrophilic nonionic surfactant include polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, and polyoxyethylene sorbitan tetraoleate); polyoxyethylene sorbitol fatty acid esters (e.g., polyoxyethylene sorbitol monolaurate, polyoxyethylene sorbitol monooleate, polyoxyethylene sorbitol pentaoleate, polyoxyethylene sorbitol monostearate); polyoxyethylene glycerin fatty acid esters (e.g., polyoxyethylene monooleate such as polyoxyethylene glycerin monostearate, polyoxyethylene glycerin monoisostearate, and polyoxyethylene glycerin triisostearate); polyoxyethylene fatty acid esters (e.g., polyoxyethylene distearate, polyoxyethylene monooleate, ethylene glycol distearate); polyoxyethylene alkyl ethers (e.g., polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene behenyl ether, polyoxyethylene 2-octyldodecyl ether, polyoxyethylene cholestanol ether); poloxamers (e.g., poloxamers); polyoxyethylene/polyoxypropylene-alkyl ethers (e.g., polyoxyethylene/polyoxypropylene-cetyl ether, polyoxyethylene/polyoxypropylene-2-decyltetradecyl ether, polyoxyethylene/polyoxypropylene-monobutyl ether, polyoxyethylene/polyoxypropylene-hydrogenated lanolin, polyoxyethylene/polyoxypropylene-glyceryl ether); tetrapolyoxyethylene/tetrapolyoxypropylene-ethylenediamine condensates (e.g., 1248612525911248312463; polyoxyethylene castor oil hardened castor oil derivatives (for example, polyoxyethylene castor oil, polyoxyethylene hardened castor oil monoisostearate, polyoxyethylene hardened castor oil triisostearate, polyoxyethylene hardened castor oil monopyroglutamic acid monoisostearic acid diester, polyoxyethylene hardened castor oil maleic acid); polyoxyethylene beeswax/lanolin derivatives (e.g., polyoxyethylene sorbitol beeswax); alkanolamides (e.g., coconut oil fatty acid diethanolamide, lauric acid monoethanolamide, fatty acid isopropanolamide); polyoxyethylene propylene glycol fatty acid esters; polyoxyethylene alkyl amines; polyoxyethylene fatty acid amides; sucrose fatty acid ester; alkyl ethoxy dimethyl amine oxide; triolein phosphoric acid.
As the higher aliphatic alcohol, for example, a higher aliphatic alcohol having 16 or more carbon atoms can be used for the purpose of achieving usability and the like. Specific examples thereof include cetyl alcohol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, and batyl alcohol.
Examples of the polyhydric alcohol include ethylene glycol, propylene glycol, 1, 3-butanediol, dipropylene glycol, polyethylene glycol, polypropylene glycol, and polybutylene glycol.
Examples of the natural water-soluble polymer include vegetable polymers (e.g., gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, locust bean gum, tamarind gum, carrageenan, pectin, agar, quince seed (quince), seaweed gum (brown algae extract), starch (rice, corn, potato, wheat), and glycyrrhizic acid); microbial polymers (e.g., xanthan gum, dextran, succinoglucan, pullulan); animal polymers (e.g., collagen, casein, albumin, gelatin).
Examples of the semisynthetic water-soluble polymer include starch-based polymers (e.g., carboxymethyl starch and methyl hydroxypropyl starch); cellulose-based polymers (methylcellulose, ethylcellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium cellulose sulfate, dialkyldimethylammonium cellulose sulfate, hydroxypropylcellulose, carboxymethylcellulose sodium, crystalline cellulose, cellulose powder, hydrophobically modified compounds of these polymers (for example, compounds partially modified with a stearyloxy group), and cationically modified compounds of these polymers); alginic polymers (e.g., sodium alginate, propylene glycol alginate); sodium pectate.
Examples of the water-soluble polymer to be synthesized include vinyl polymers (e.g., polyvinyl alcohol, polyvinyl methyl ether, polyvinyl pyrrolidone, carboxyvinyl polymer); polyoxyethylene polymers (for example, polyoxyethylene polyoxypropylene copolymers of polyethylene glycol 20,000, 40,000, and 60,000); a poly (dimethyldiallylammonium halide) type cationic polymer; a copolymer type cationic polymer of dimethyldiallylammonium halide and acrylamide; acrylic polymers (e.g., sodium polyacrylate, polyethylacrylate, polyacrylamide); a polyethyleneimine; a cationic polymer; silicic acid AlMg (1249912540\\ 1246012512.
Examples of the ultraviolet absorber include benzoic acid-based ultraviolet absorbers (for example, p-aminobenzoic acid (hereinafter abbreviated as "PABA"), PABA monoglyceride, N-dipropoxypPABA ethyl ester, N-diethoxypPABA ethyl ester, N-dimethylpPABA ethyl esterButyl ester, N-dimethyl PABA ethyl ester); anthranilic acid-based ultraviolet absorbers (e.g., high
Figure BDA0003990713500000171
phenyl-N-acetyl anthranilate); salicylic acid-based ultraviolet absorbent (e.g., amyl salicylate, salicylic acid->
Figure BDA0003990713500000172
Ester and salicylic acid high->
Figure BDA0003990713500000173
Esters, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropyl phenyl salicylate); cinnamic acid-based ultraviolet absorbers (for example, octyl cinnamate, ethyl-4-isopropyl cinnamate, methyl-2, 5-diisopropyl cinnamate, ethyl-2, 4-diisopropyl cinnamate, methyl-2, 4-diisopropyl cinnamate, propyl-p-methoxy cinnamate, isopropyl-p-methoxy cinnamate, isopentyl-p-methoxy cinnamate, octyl-p-methoxy cinnamate (2-ethylhexyl-p-methoxy cinnamate), 2-ethoxyethyl-p-methoxy cinnamate, cyclohexyl-p-methoxy cinnamate, ethyl- α -cyano- β -phenyl cinnamate, 2-ethylhexyl- α -cyano- β -phenyl cinnamate, glyceryl mono-2-ethylhexanoyl-p-methoxy cinnamate); benzophenone-based ultraviolet absorbers (for example, 2, 4-dihydroxybenzophenone, 2' -dihydroxy-4-methoxybenzophenone, 2' -dihydroxy-4, 4' -dimethoxybenzophenone, 2', 4' -tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4 ' -methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl-4 ' -phenyl-benzophenone-2-carboxylate, 2-hydroxy-4-n-octyloxybenzophenone, 4-hydroxy-3-carboxybenzophenone); 3- (4' -methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor; 2-phenyl-5-methylbenzo->
Figure BDA0003990713500000181
Azole; 2,2' -hydroxy-5-methylphenylbenzotriazole; 2- (2 '-hydroxy-5' -tert-octylphenyl) benzotriazole; 2- (2 ' -hydroxy-5 ' -methylphenylbenzotriazole, dianisiloylmethane, 4-methoxy-4 ' -tert-butyldibenzoylmethane, 5- (3, 3-dimethyl-2-norbornylene) -3-pentan-2-one); triazine-based ultraviolet absorber (e.g., 2-4[ (2-hydroxy-3-dodecyloxypropyl) oxy group)]-2-hydroxyphenyl) -4, 6-bis (2, 4-dimethylphenyl) -1,3, 5-triazine, 2-4[ (2-hydroxy-3-tridecyloxypropyl) oxy]-2-hydroxyphenyl) -4, 6-bis (2, 4-dimethylphenyl) -1,3, 5-triazine).
Examples of the sequestering agent include 1-hydroxyethane-1, 1-diphosphonic acid, 1-hydroxyethane-1, 1-diphosphonic acid tetrasodium salt, ethylenediaminetetraacetic acid disodium salt, ethylenediaminetetraacetic acid trisodium salt, ethylenediaminetetraacetic acid tetrasodium salt, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, ethylenediaminetetraacetic acid, and ethylenediamine hydroxyethyltriacetic acid 3 sodium salt.
Examples of the pH adjuster include buffers such as sodium lactate-lactate, sodium citrate-citrate, and sodium succinate-succinate.
Examples of the vitamins include vitamin a, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin E, and derivatives thereof, pantothenic acid and derivatives thereof, and biotin.
Examples of the antioxidant include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, and gallic acid esters.
Examples of the antioxidant auxiliary include phosphoric acid, citric acid, ascorbic acid, maleic acid, malonic acid, succinic acid, fumaric acid, cephalin, hexametaphosphate, phytic acid, and ethylenediaminetetraacetic acid.
Examples of other optional components that can be compounded include preservatives (e.g., ethyl p-hydroxybenzoate, butyl p-hydroxybenzoate, 1, 2-alkanediol, phenoxyethanol, methylchloroisothiazolinone); anti-inflammatory agents (e.g., glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin); whitening agent (e.g., saxifrage extract, arbutin); various extracts (e.g., amur corktree bark, coptis chinensis, lithospermum, paeonia lactiflora, swertia japonica, birch, sage, loquat, carrot, aloe, mallow, iris, grape, coix seed, luffa, lily, saffron, ligusticum wallichii, ginger, hypericum erectum, formononetin, garlic, capsicum, dried orange peel, angelica, seaweed), activators (e.g., royal jelly, photosensitizer, cholesterol derivative); blood circulation promoters (e.g., vanillyl nonanoate, benzyl nicotinate, β -butoxyethyl nicotinate, capsaicin, zingerone, cantharides, ichthammol, tannic acid, α -borneol, tocopheryl nicotinate, inositol hexanicotinate, cyclamate, cinnarizine, tolazolin, acetylcholine, verapamil, cepharanthine, γ -oryzanol); anti-lipemic agents (e.g., sulfur, dimethyl thianthrene); anti-inflammatory agents (e.g., tranexamic acid, thiotaurine, hypotaurine); aromatic alcohols (benzyl alcohol, benzyloxyethanol); humectants (e.g., glycerin for dana explosives); a thickener; a coating agent; a skin nutrient; perfumes other than those described above (e.g., limonene (LogP: 4.8), damascone (LogP: 4.3)); a scrubbing agent.
Use of oil-in-water emulsion composition
The oil-in-water emulsion composition of the present disclosure can be suitably used as a preparation to be applied to the skin, for example, a skin external preparation such as a cosmetic, a quasi-drug, or a pharmaceutical.
The emulsion composition of the present disclosure may be in the form of, for example, an emulsion, a paste, or a liquid.
When the emulsion composition of the present disclosure is used in the field of cosmetics, for example, the product form thereof is not particularly limited, and examples thereof include facial cosmetics such as a lotion, a beauty lotion, an emulsion, and a mask; makeup cosmetics such as foundation make-up and eye shadow; sunscreen cosmetics (sunscreens); a body cosmetic; skin washing materials such as makeup remover, body shampoo, etc.; hair cosmetics such as shampoo, hair tonic, hair conditioner, shampoo, rinse, and hair tonic; shaving cosmetics such as shaving cream, water before beard, and water after beard; ointments and the like.
Method for producing oil-in-water emulsion composition
The emulsion composition of the present disclosure can be prepared by a known method such as a dispersion method or an aggregation method.
The dispersion method is a method of making a bulk of a dispersed phase into fine particles by a mechanical force. Specifically, the emulsification is performed by the crushing force of an emulsifier, and examples of such a method include a high-pressure emulsification method in which a high shearing force is applied by using a high-pressure homogenizer.
The agglutination method is a method of preparing a colloid using surface chemical properties, and a supersaturated state is formed by some means from a uniformly dissolved state, and a substance which becomes a dispersed phase appears. As specific methods, for example, HLB temperature emulsification, phase inversion emulsification, nonaqueous emulsification, D phase emulsification, and liquid crystal emulsification are known. Among them, the D-phase emulsification method is preferable from the viewpoint of emulsion stability and the like.
As an example, a suitable production method of the emulsion composition of the present disclosure will be described below.
A first aqueous phase part 1 containing the nonionic surfactant and anionic surfactant of the formulae 1 to 3 and water was prepared. Next, an oil phase portion containing a drug having a LogP value of-0.7 to 4.0 and an oil component was prepared. A pre-emulsion was prepared by mixing the oil phase part with all or a part of the 1 st aqueous phase part. When the 1 st aqueous phase portion remains, the pre-emulsion may be mixed with the remaining portion of the 1 st aqueous phase portion, and when the 1 st aqueous phase portion does not remain, the pre-emulsion may be mixed with the 2 nd aqueous phase portion containing water to prepare the oil-in-water emulsion composition of the present disclosure.
For example, the anionic surfactant may be mixed in the aqueous phase part and the nonionic surfactants of formulae 1 to 3 may be mixed in the oil phase part, but the emulsion stability may be further improved by mixing the nonionic surfactants of formulae 1 to 3 and the anionic surfactant in the aqueous phase part, particularly the 1 st aqueous phase part, at the same time.
From the viewpoint of obtaining fine and uniform emulsified particles (oil droplets), it is preferable to blend a glycol in the 1 st aqueous phase part. Examples of the diol include at least one diol component selected from dipropylene glycol, 1, 3-butanediol, propylene glycol, and polyethylene glycol.
The amount of the diol component or the like to be blended is not particularly limited, and may be, for example, 40 mass% or more, 45 mass% or more, or 50 mass% or more, or 80 mass% or less, 75 mass% or less, or 70 mass% or less, based on the total amount of the aqueous phase portion.
The aqueous phase portion and/or the oil phase portion may optionally be warmed. The temperature for heating is not particularly limited, and may be, for example, 40 ℃ or higher, 50 ℃ or higher, or 60 ℃ or higher, or 90 ℃ or lower, 80 ℃ or lower, or 70 ℃ or lower.
Examples
The present disclosure will be described in further detail below with reference to examples, but the present disclosure is not limited thereto. In the following, unless otherwise specified, the blending amount is expressed in parts by mass.
EXAMPLES 1 TO 2 AND COMPARATIVE EXAMPLES 1 to 5
The following evaluations were made with respect to the oil-in-water emulsion compositions obtained by the formulations shown in table 1 and the production methods shown below, and the results are shown in table 1.
Evaluation method
( Emulsion stability test: evaluation based on average particle diameter of oil droplets )
The average particle size of oil droplets (emulsified particles) in the oil-in-water type emulsion composition was determined as an average value of equivalent circle diameters of projected areas of arbitrarily selected 10 oil droplets, which was directly observed by visual observation with an optical microscope (BX 53, manufactured by OLYMPUS). The average particle size was measured immediately after the preparation of the composition, after the composition was stored at 50 ℃ for 30 days, and after the composition was stored at 0 to 40 ℃ for 30 days under temperature cycling conditions (0 to 40 ℃ C. Was subjected to 2 cycles/day, and the composition was left at 0 ℃ C. And 40 ℃ C. For 2 hours).
The increase rate of oil droplets was calculated from the value of the average particle size of oil droplets immediately after production and the value of the average particle size of oil droplets after storage at 50 ℃ for 30 days or storage at 0 to 40 ℃ under temperature cycle conditions, by the following formula 5. In table 1, for example, when the average particle size of oil droplets is expressed as "2 to 10", 6 μm (= (2 + 10)/2), which is an average value of values obtained by adding the lower limit value and the upper limit value, is introduced into formula 5:
an increase rate (%) = { (value of average particle size of oil droplets after storage at 50 ℃ for 30 days or storage at 0 to 40 ℃ under temperature cycle conditions for 30 days-value of average particle size of oil droplets immediately after production) × 100 }/(value of average particle size of oil droplets immediately after production) \82305: (formula 5)
The emulsion stability was evaluated by the following evaluation criteria using the increase rate of oil droplets after storage for 30 days under the temperature cycle condition of 0 to 40 ℃. Here, the a and B evaluations are achieved as passed, and the C and D evaluations are failed.
A: the oil droplets are increased by 10% or less.
B: the oil droplets increase in percentage by more than 10% and not more than 50%.
C: the oil droplets increase at a rate of more than 50% and 100% or less.
D: the oil droplets increased more than 100%.
Method for producing oil-in-water type emulsified composition
(example 1)
Using the formulations shown in table 1, an oil-in-water emulsion composition was produced by the following method. Here, the numbers shown below correspond to the numbers of the components shown on the left side of the prescription in table 1.
The surfactants of Nos. 1 to 3 and 5 and the materials of Nos. 16 to 21 were added to a part of the ion-exchanged water of No.15, and the mixture was uniformly mixed while heating to 70 ℃ to prepare the No.1 aqueous phase portion.
After the oils of nos. 9 to 13 were uniformly mixed, the drug of No.14 was added and uniformly mixed to prepare an oil phase portion.
An oil phase part was added to the 1 st aqueous phase part, and the mixture was uniformly mixed to prepare a pre-emulsion. The remaining part of ion-exchanged water No.15 (the 2 nd aqueous phase part) was added to the pre-emulsion and uniformly mixed to prepare the oil-in-water emulsion composition of example 1.
(example 2 and comparative examples 1 to 5)
Oil-in-water emulsion compositions of example 2 and comparative examples 1 to 5 were prepared in the same manner as in example 1, except that the formulations in table 1 were changed. Here, the nonionic surfactants No.6 and No.7 in Table 1 were added simultaneously when preparing the aqueous phase part, and the behenyl alcohol No.8 was added simultaneously when preparing the oil phase part.
Figure BDA0003990713500000231
/>
Results
As is clear from table 1, in the case of the emulsion composition of comparative example 1 containing the nonionic surfactant of formulae 1 to 3 but not the anionic surfactant, the increase rate of oil droplets after 30 days storage at 50 ℃ could be suppressed to about 50%, but the increase accompanied by coalescence of oil droplets could not be suppressed after 30 days storage under the temperature cycle condition of 0 to 40 ℃.
Further, the emulsion compositions of comparative examples 2 and 3 using other nonionic surfactants and anionic surfactants could not suppress the increase of oil droplets even after 30 days of storage at 50 ℃.
Further, in the emulsion compositions of comparative examples 4 and 5 using a surfactant and a higher fatty alcohol having a property of enhancing an interface film, the increase of oil droplets was not suppressed even after storage for 30 days under a temperature cycle condition of 0 to 40 ℃.
On the other hand, in the case of the emulsion compositions of examples 1 and 2 containing an anionic surfactant in addition to the nonionic surfactant of formulae 1 to 3, no increase in oil droplets was observed both after storage at 50 ℃ for 30 days and after storage at 0 to 40 ℃ under temperature cycle conditions for 30 days, and good emulsion stability was obtained.
Further, it is also known that the emulsion compositions of examples 1 and 2 do not contain higher fatty alcohol, and therefore, the sticky feeling can be reduced as compared with the emulsion compositions of comparative examples 4 and 5.
Prescription of oil-in-water emulsion composition
Examples of formulations of the oil-in-water emulsion composition of the present disclosure are given below, but the present disclosure is not limited to these examples.
Prescription example 1: emulsion (II)
Figure BDA0003990713500000241
/>
Figure BDA0003990713500000251
Prescription example 2: emulsion (II)
Figure BDA0003990713500000252
/>
Figure BDA0003990713500000261
Prescription example 3: emulsion (II)
Figure BDA0003990713500000262
Figure BDA0003990713500000271
Prescription example 4: emulsion (lotion)
Figure BDA0003990713500000272
Figure BDA0003990713500000281
The above-mentioned components were emulsified by a conventional method to obtain emulsions. The emulsion obtained was excellent in emulsion stability.
Prescription example 5: non-alcoholic perfume-
Figure BDA0003990713500000282
The above components are emulsified by a conventional method to obtain an alcohol-free perfume. The obtained alcohol-free perfume has excellent emulsion stability.

Claims (9)

1. An oil-in-water emulsion composition comprising:
an aqueous dispersion medium, and
oil droplets dispersed in the aqueous dispersion medium,
the oil droplets contain a medicament, a surfactant and an oil component,
the agent has a LogP value of-0.7 to 4.0,
the surfactant comprises a nonionic surfactant represented by the following formula 1 to formula 3 and an anionic surfactant,
Figure FDA0003990713490000011
in the formula 1, the first and second groups,
R 1 is a linear acyl group or a linear alkyl group having 16 to 24 carbon atoms,
R 2 is an alkyl group having 2 to 4 carbon atoms,
R 3 is a linear acyl group or a linear alkyl group having 16 to 24 carbon atoms,
k is an integer of 4 to 15;
Figure FDA0003990713490000012
in the formula 2, the first and second groups,
R 4 is a straight-chain fatty acid residue or a straight-chain fatty alcohol residue with 16 to 24 carbon atoms,
R 5 is an alkyl group having 2 to 4 carbon atoms,
k is an integer of 5 to 20;
Figure FDA0003990713490000013
in the formula 3, the first and second groups,
R 6 is a cholesterol residue or a phytosterol residue,
R 7 is an alkyl group having 2 to 4 carbon atoms,
k is an integer of 5 to 30.
2. The composition according to claim 1, wherein the content of the pharmaceutical agent in the composition is 0.1 to 5% by mass relative to the total amount of the composition.
3. The composition according to claim 1 or 2, wherein the nonionic surfactant represented by the formula 1 is contained in an amount of 0.1 to 2% by mass based on the total amount of the composition,
the content of the nonionic surfactant represented by the formula 2 in the composition is 0.1 to 2% by mass based on the total amount of the composition,
the content of the nonionic surfactant of formula 3 in the composition is 0.3 to 6% by mass relative to the total amount of the composition, and,
the content of the anionic surfactant in the composition is 0.01 to 0.1% by mass relative to the total amount of the composition.
4. The composition according to any one of claims 1 to 3, wherein the anionic surfactant is at least one selected from the group consisting of alkanoyl-N-alkyltaurates and alkanoyl glutamates.
5. The composition according to any one of claims 1 to 4, wherein the agent is at least one selected from the group consisting of phenylethyl resorcinol, 4- (1-phenylethyl) -1, 3-diol, phenoxythiazolidine carboxylic acid, nicotinamide, xanthine, ellagic acid, ferulic acid, apigenin, salicylic acid, phloretin, resveratrol and perfume.
6. The composition according to any one of claims 1 to 5, wherein the oil component is at least one selected from the group consisting of liquid oils and fats, solid oils and fats, waxes, hydrocarbon oils, higher fatty acids, synthetic ester oils, and silicone oils.
7. The method for producing an oil-in-water emulsion composition according to any one of claims 1 to 6,
preparing a 1 st aqueous phase part containing the nonionic surfactant of the formulae 1 to 3, the anionic surfactant, and water,
preparing an oil phase part comprising the drug and the oil component,
mixing the oil phase part with part or all of the 1 st aqueous phase part to prepare a pre-emulsion,
mixing the pre-emulsion with the remainder of the 1 st aqueous phase portion, or mixing the pre-emulsion with a 2 nd aqueous phase portion comprising water.
8. The production method according to claim 7, wherein the 1 st aqueous phase portion contains at least one diol component selected from dipropylene glycol, 1, 3-butanediol, propylene glycol, and polyethylene glycol.
9. The production process according to claim 8, wherein the content of the diol component is 40 to 80% by mass based on the total amount of the first aqueous phase portion 1.
CN202180041818.6A 2020-07-09 2021-06-25 Oil-in-water type emulsion composition Pending CN115942929A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020118553 2020-07-09
JP2020-118553 2020-07-09
PCT/JP2021/024241 WO2022009709A1 (en) 2020-07-09 2021-06-25 Oil-in-water emulsion composition

Publications (1)

Publication Number Publication Date
CN115942929A true CN115942929A (en) 2023-04-07

Family

ID=79553007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041818.6A Pending CN115942929A (en) 2020-07-09 2021-06-25 Oil-in-water type emulsion composition

Country Status (3)

Country Link
JP (1) JPWO2022009709A1 (en)
CN (1) CN115942929A (en)
WO (1) WO2022009709A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6426635B2 (en) * 2016-01-27 2018-11-21 株式会社 資生堂 Composition for alpha gel formation and alpha gel composition
BR112018015056B1 (en) * 2016-01-27 2022-05-03 Shiseido Company, Ltd Alpha-gel forming compositions

Also Published As

Publication number Publication date
JPWO2022009709A1 (en) 2022-01-13
WO2022009709A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
RU2607088C1 (en) &#34;core-shell&#34; type microgel emulsifier and &#34;oil-in-water&#34; emulsion composition
TWI394590B (en) Water-based emulsified sunscreen makeup
CN108472230B (en) Composition for forming alpha gel, and composition for external application to skin and alpha gel composition using same
RU2645110C1 (en) Initial material for cosmetic products
US20100297039A1 (en) Oil-In-Water Emulsion Composition And Method For Producing The Same
ES2710297T3 (en) Intermediate alpha gel compositions, and production process for O / W emulsion cosmetic containing alpha gel using said composition
ES2724463T3 (en) Intermediate composition of alpha gel, and production process for cosmetic in O / W emulsion containing alpha gel using said composition
CN110461301B (en) Oil-in-water type cosmetic
KR19980069385A (en) UV absorbing composition
KR102251072B1 (en) Oil-in-water emulsion composition
US20040197361A1 (en) External preparation for the skin
TWI795417B (en) Powder containing water based unemulsified composition and external medicine for skin
CN108472224B (en) Composition for forming alpha gel and alpha gel composition
CN115942929A (en) Oil-in-water type emulsion composition
CN115279332A (en) Composition containing lamellar gel, emulsified composition and external composition for skin
WO2024075548A1 (en) Gel composition and oil-in-water-type composition
JP2023048020A (en) W/o type emulsified cosmetic or external preparation
JP2023048360A (en) W/o emulsion cosmetic or topical preparation
JP2023179827A (en) O/w/o emulsion composition
WO2022210144A1 (en) Oil-in-water cosmetic composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination